On May 1st and 2nd I had the pleasure of representing CBCN at an Advisory Committee meeting for the Inuit Cancer Project lead by Pauktuutit Inuit Women of Canada in Iqaluit, NU. This meeting gave those involved in the project an opportunity to meet face to face to discuss an overview of the project, how it was proceeding, along with an update of recent activities and roundtable discussions. These roundtable discussions included opportunities to speak about lessons learned, ways to build community engagement, community capacity and next steps.
As a breast cancer survivor and board member of CBCN, I am very interested in how biosimilars will be used in breast cancer treatment in Canada. While not commonly understood today, biosimilars will soon be a household discussion among breast cancer patients. As patients, it is important for us to know how biosimilars will be used to treat cancer, especially if they are going to be used as effective alternatives to brand name treatments. Here are some of the points that I think are important for us, as patients, to consider.
Earlier this month, the annual meeting for the American Society of Clinical Oncology was held in Chicago. Here, key research developments in every area of cancer care are shared with oncology professionals from around the world. We’ve compiled the top breast cancer highlights to come out of this year’s ASCO 2018 conference:
I have been living with metastatic breast cancer for over eight years. While I am usually averse to using battle analogies for living with and dying from cancer, finding the best care has required a fight, considerable perseverance, and hard work. Fortunately, my ER+/PR+ tumours (pleura/liver/lymph) have responded well, but not great, to hormonal therapies. I’m onto my seventh line of treatment.
Dense breasts are common in Canadian women, affecting about 3.4 million women. Having dense breasts makes it harder to detect cancer on a mammogram yet women are not being told.
Now that you’ve learned more about biosimilars, it may also be of interest to learn what the physician perspective is. We connected with Dr. Sandeep Sehdev, a medical oncologist at the Ottawa Hospital, to get his perspective on biosimilars and what he thinks is important for patients to understand about them.
One of the most common complaints you hear from patients getting chemotherapy is brain fog. It's why it's most commonly known as "chemo brain". But what is it and why does it happen? And most importantly, how can it be managed?
Biosimilar drugs will soon be entering the breast cancer treatment landscape and are already available for support medications. With these emerging treatment options, it’s important to know more about them so you can make informed decisions about your treatment plan.
In complete contrast to constipation, diarrhea is also a common side effect of treatment. While many chemotherapies and targeted therapies cause constipation, some of the others cause diarrhea. Loss of bowel control can not only be embarrassing, but it can cause painful cramps and lead to dehydration.
It’s powerful what happens when patients, caregivers, and clinicians come together to look at research priorities; a broad list of questions that encompasses a variety of viewpoints emerges.
Poop, definitely a topic that most of us don’t want to have candid conversations about, especially when it comes to our own. But constipation is one of the most common side effects of many cancer treatments, and can be a real pain in the a**, literally.
Clinical trials play a big role in the discovery of new treatments for cancer. They help to determine the safety and effectiveness of potential new treatments. For metastatic patients, they can also potentially offer additional treatment options after the cancer has grown resistant to the standards of care.
I went for my regularly scheduled mammogram in April 2014. The notice I received for my mammogram stated that I was to be screened annually because I had 'dense breast tissue’. This was the first time I had heard that term. When I went for my mammogram in Regina, I told the tech that my letter stated that I had 'dense breast tissue’. After the mammogram, she looked at the images and said yes, “dense breasts.” I had no idea what this meant for me, but I was to find out soon.
Here are some highlights from the latest in breast cancer research:
About 10 years ago, Charlotte Pennell was pruning bushes in her garden in Winnipeg. One branch seemed especially tough to cut. Then she looked down and saw that she was cutting her finger. She was horrified that she had so little feeling in her hand.
For Jenn Abbott, finishing treatment for breast cancer is like a flying trapeze. Having received her “NED” (no evidence of disease), she is in mid-air, no longer holding on to the bar that represents the medical team that saved her life, while at the same time, not yet catching the second bar that represents the rest of her life after cancer. She is in limbo, facing post-traumatic stress disorder brought on by her cancer treatment which included five surgeries and a severe adverse reaction to chemotherapy that meant she had to stay in the hospital for two weeks. She feels PTSD after cancer treatment is real.
January 4, 2010, I became a fly on the wall. I was at my surgeon’s getting results from my biopsy. It was supposed to be a quick appointment as the initial needle test of fluid prior to the biopsy was negative for cancer, or so we thought. I remember hearing the doctor telling me “unfortunately it was cancer….” I felt like I was having an out of body experience. I was there but literally watching over my body and the doctor from a distance. My world suddenly changed both physically and mentally.
I’m from Ottawa. I was diagnosed de novo in March 2011 with metastatic breast cancer and metastasis to the bone. I am 53 years old. I am a mother, daughter, sister, artist, lesbian, atheist, and gardener.